Astellas Pharma (OTCMKTS:ALPMY) Hits New 1-Year Low – Here’s What Happened

Astellas Pharma Inc. (OTCMKTS:ALPMY) shares reached a new 52-week low during mid-day trading on Friday . The company traded as low as $9.00 and last traded at $9.19, with a volume of 261280 shares changing hands. The stock had previously closed at $9.22.

Astellas Pharma Price Performance

The company has a debt-to-equity ratio of 0.39, a current ratio of 1.04 and a quick ratio of 0.80. The company has a market cap of $16.63 billion, a PE ratio of -41.77 and a beta of 0.29. The stock has a fifty day moving average price of $9.72 and a 200-day moving average price of $10.34.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings data on Tuesday, February 4th. The company reported $0.30 EPS for the quarter. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. On average, equities analysts expect that Astellas Pharma Inc. will post 0.42 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.